Business Description
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Business History
Price Overview
Last updated: Jun 30, 2026 4:46am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.16
Total Equity: $33.02M
Shares: 41,636,849
Total Debt: $0.00
Cash: $30.11M
EBITDA: -$13.35M
Total Debt: $0.00
Cash: $30.11M
Revenue: $0.00
Shares: 41,636,849
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $33.02M
Tax Rate: 0.0%
Equity: $33.02M
Total Debt: $0.00
Cash: $30.11M
Current Liabilities: $3.84M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $33.02M
Shares: 41,636,849
Shares: 41,636,849
CapEx: -$7,000
Shares: 41,636,849
Stock Price: $1.98
Net Income: -$6.61M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 30, 2026 4:46am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $88.0M | -$10.7M | $4.5M | $0 | $0 |
| Cost of Revenue | $46.4M | $0 | $0 | $0 | $0 |
| Gross Profit | $41.6M | -$10.7M | $4.5M | $0 | $0 |
| Operating Expenses | $2.1B | $355.4M | $515.6M | $375.4M | $13.5M |
| Operating Income | -$2.1B | -$366.1M | -$511.2M | -$375.4M | -$13.5M |
| Net Income | -$2.3B | -$2.5B | -$1.5B | -$162.3M | -$6.6M |
| EBITDA | -$2.1B | -$51.2M | -$344.3M | -$373.5M | -$13.4M |
| EPS | $-30.70 | $-30.38 | $-17.62 | $-4.46 | $-0.16 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 30, 2026 4:46am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $552.8M | $3.2B | $291.5M | $498.2M | $30.1M |
| Total Current Assets | $750.2M | $3.6B | $329.9M | $1.3B | $31.1M |
| Total Assets | $878.7M | $4.1B | $368.9M | $1.6B | $37.2M |
| Current Liabilities | $97.9M | $659.7M | $58.1M | $61.7M | $3.8M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $163.4M | $1.1B | $126.3M | $84.1M | $4.2M |
| Total Equity | $715.3M | $3.0B | $242.6M | $1.5B | $33.0M |
| Retained Earnings | -$683.2M | -$6.8B | -$1.3B | -$9.4B | -$190.5M |
Cash Flow (Annual)
Last updated: Jun 30, 2026 4:46am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$973.1M | -$1.1B | -$72.9M | -$384.4M | -$20.6M |
| Capital Expenditure | -$29.9M | -$45.8M | $-164,354 | $-350,342 | $-7,000 |
| Free Cash Flow | -$1.0B | -$1.1B | -$73.0M | -$384.8M | -$20.6M |
| Acquisitions (net) | -$6.0M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$3.1M | -$8.7M | -$2.4M | $0 |
| Net Change in Cash | -$1.2B | -$212.9M | -$151.6M | -$1.7B | $142.4M |
Analyst Estimates (Annual)
Last updated: Jun 30, 2026 4:46am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 |
$106.6M $106.6M – $106.6M
|
$167.8M $167.8M – $167.8M
|
$436.1M $436.1M – $436.1M
|
| EBITDA | $0 |
$21.3M $21.3M – $21.3M
|
$33.6M $33.6M – $33.6M
|
$87.2M $87.2M – $87.2M
|
| Net Income |
-$206.4M -$206.4M – -$206.4M
|
-$220.6M -$220.6M – -$220.6M
|
-$241.8M -$241.8M – -$241.8M
|
-$222.0M -$222.0M – -$222.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 30, 2026 4:46am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -112.2% | +141.9% | -100.0% | — |
| Gross Profit Growth | -125.7% | +141.9% | -100.0% | — |
| Operating Income Growth | +82.3% | -39.6% | +26.6% | +96.4% |
| Net Income Growth | -7.5% | +41.5% | +88.9% | +95.9% |
| EBITDA Growth | +97.5% | -572.0% | -8.5% | +96.4% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Cao Sean Wuxiong | A-Award | 181,290.00 | $1.53 | $277,374 |
| 2026-06-22 | Cao Sean Wuxiong | A-Award | 181,280.00 | $0.00 | $0 |
| 2026-06-17 | Dennis Phillip Andrew | M-Exempt | 23,695.00 | $0.00 | $0 |
| 2026-06-18 | Dennis Phillip Andrew | S-Sale | 8,494.00 | $0.66 | $5,606 |
| 2026-06-17 | Dennis Phillip Andrew | M-Exempt | 10,302.00 | $0.00 | $0 |
| 2026-05-30 | Xu Cong Claire | M-Exempt | 9,382.00 | $0.00 | $0 |
| 2026-06-01 | Xu Cong Claire | S-Sale | 3,494.00 | $3.94 | $13,766 |
| 2026-05-30 | Xu Cong Claire | M-Exempt | 4,079.00 | $0.00 | $0 |
| 2026-05-14 | Cao Sean Wuxiong | S-Sale | 21,399.00 | $1.99 | $42,584 |
| 2026-04-24 | Hagler Mark Arnold | P-Purchase | 230,000.00 | $2.51 | $577,300 |
| 2026-04-17 | Hagler Mark Arnold | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Xu Cong Claire | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Yang Conor Chia-hung | 114,093.00 | $1.22 | $139,193 | |
| 2026-03-18 | Yang Conor Chia-hung | 34,530.00 | $3.86 | $133,286 | |
| 2026-03-18 | Chu Denny Hsueh Wen | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Dennis Phillip Andrew | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Dennis Phillip Andrew | 186,300.00 | $1.05 | $195,615 | |
| 2026-03-18 | Dennis Phillip Andrew | 494,510.00 | $1.82 | $900,008 | |
| 2026-03-18 | Dennis Phillip Andrew | 92,724.00 | $0.00 | $0 | |
| 2026-03-18 | Lin Liwei Lorraine | 0.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).